Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective - 22/07/20

Key words : COVID-19, immunodeficiency, passive immunity, plasma therapy, IVIG, mAb
El texto completo de este artículo está disponible en PDF.
This work was supported by the Swedish Research Council and the European Commission Horizon 2020 program (grant no. 101003650-ATAC). |
|
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 1
P. 58-60 - juillet 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.